Last reviewed · How we verify
NCT06931145
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Phase 4 trial testing Benmelstobart in Extensive-stage Small Cell Lung Cancer in 50 participants. Not yet recruiting.
30 April 2027
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 15 April 2025 |
| Primary completion | 30 April 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Benmelstobart — full drug profile →
- Anlotinib — full drug profile →
- Carboplatin or cisplatin — full drug profile →
- Etoposide (etoposide) — full drug profile →
Conditions studied
- Extensive-stage Small Cell Lung Cancer — all drugs for Extensive-stage Small Cell Lung Cancer →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 75, any sex, with Extensive-stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.
Parmar K, Surolia I, Thomas A. · · 2026 · PMID 42147254 · DOI 10.3389/fonc.2026.1821271 -
Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era.
Cheng P, Gu H, Chen Q, Zhao G, et al · · 2026 · PMID 42052493 · DOI 10.3389/fonc.2026.1748214
Verify or expand the search:
- PubMed search for NCT06931145
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Benmelstobart
Trials testing the same drug.
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07385079 — Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma · Phase 3 · not yet recruiting
- NCT06992336 — Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuv · Phase 2 · recruiting
- NCT06699498 — Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC · Phase 2 · not yet recruiting
- NCT06603974 — The Efficacy and Safety of Benmelstobart for GC/EGC · NA · not yet recruiting
Other recruiting trials for Extensive-stage Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06479473 — Radiotherapy to All Residual Lesions After Chemoimmunotherapy · Phase 1, PHASE2 · recruiting
- NCT04397003 — Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer · Phase 2 · active not recruiting
- NCT04702880 — A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage · Phase 2 · active not recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06931145 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 23 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06931145.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing